SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

The AMP token is trending amidst intense community debate over its long-term viability and recent price decline, with sentiment split between disillusioned "bagholders" calling it a failed project and resilient believers clinging to hopes of institutional adoption and regulatory clarity. While the community actively questions leadership transparency and the lack of tangible network usage, the recurring presence of the symbol in top trending charts continues to drive speculation about potential utility-driven rebounds.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

$TRUMP.X is facing intense community backlash following financial disclosures revealing the Trump family earned over $1 billion from crypto ventures while most retail holders have seen their investments collapse. Investors are actively debating whether the token is a failed pump-and-dump scheme or a potential value opportunity, with significant tension between those calling it a grift and those framing the market volatility as a typical speculative casino.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as investors focus on the commercial ramp-up of ZEVASKYN, with community discussions centering on the rollout of qualified treatment centers and the potential for near-term profitability. Sentiment is driven by anticipation of upcoming earnings and clinical milestones, while active traders closely monitor high short interest and institutional accumulation patterns.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors monitor the company's critical role in the data center infrastructure buildout, specifically its partnership for power generation solutions. The community is heavily focused on potential project announcements, the impact of sector-wide power constraints, and the stock's recent volatility as it navigates both institutional interest and short-seller scrutiny.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending as investors focus on its strong earnings momentum and the upcoming launch of its new oncology drug, Veppanu. While the community is actively debating the company's long-term valuation and potential for a strategic buyout, discussions remain centered on the company's profitability and its expanding commercial oncology pipeline.

Global X Funds - Global X Silver Miners ETF

Silver miners are trending as investors weigh strong industrial demand and global supply shortages against recent market volatility and aggressive margin hikes by exchanges. The community remains focused on the potential for a significant 'catch-up' rally in mining equities as participants anticipate strong upcoming quarterly earnings.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is seeing increased momentum as the market recognizes the potential of its ultra-sensitive MRD platform, particularly following new Medicare coverage milestones and ongoing institutional interest from key industry partners. Investors are closely monitoring the upcoming earnings call for evidence of commercial traction and revenue growth as the company pivots from clinical development to broader market adoption.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is currently trending as the community debates its long-term utility against market volatility, with many users actively accumulating tokens and increasing staking positions. Discussions center on the project's institutional payroll partnerships, the release of the Zebec SuperApp, and anticipation for regulatory clarity to drive future adoption.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its role in the emerging 'agentic economy' and AI-native infrastructure, with community sentiment split between those accumulating for long-term utility and traders wary of short-term volatility. The conversation is currently dominated by debate over its technical integration with AI agents and whether it can maintain momentum as a key layer for decentralized computation.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: U.S. Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, U.S. Rod and Refining, Atlantic Copper, and Corporate and Other. The U.S. Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The U.S. Rod and Refining segment consists of copper conversion facilities located in North America and includes refinery and rod mills. The Atlantic Copper segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is trending as investors capitalize on a structural global copper deficit driven by surging AI infrastructure needs and electrification, which some analysts believe positions the stock for long-term growth. Community discussion is heavily focused on the disconnect between the metal's supply-constrained outlook and recent share price volatility, with many traders accumulating on dips to gain exposure to an asset class they view as essential to future technological and industrial capacity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BCTX this has been a terrible stock for longs and a  great stock for traders. Buy after offering, sell immediately on postive PR. Rinse and repeat. That will change sometime over the next year.  I fully expect another offering, but full approval will re-rate this much, much higher. Traders might be on the outside looking in.  Anyone holding a core and trading around that?

Tyler

StockTwits For Android 

BriaCell Therapeutics Corp

 this has been a terrible stock for longs and a  great stock for traders. Buy after offering, sell immediately on postive PR. Rinse and repeat. That will change sometime over the next year.  I fully expect another offering, but full approval will re-rate this much, much higher. Traders might be on the outside looking in.  Anyone holding a core and trading around that?